BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects

Current Cancer Drug Targets - United Arab Emirates
doi 10.2174/1568009614666140121150930
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Beyond BRAF: Where Next for Melanoma Therapy?

British Journal of Cancer
Cancer ResearchOncology
2014English

Grp94-Specific Monoclonal Antibody to Counteract BRAF Inhibitor Resistance in BRAFV600E Melanoma

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Inhibition of YAP Function Overcomes BRAF Inhibitor Resistance in Melanoma Cancer Stem Cells

Oncotarget
Oncology
2017English

Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

809 Pou4f1 Promotes Braf Inhibitor Resistance by Reactivating Mapk Signaling Pathway in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Development of Encorafenib for BRAF-mutated Advanced Melanoma

Current Opinion in Oncology
Cancer ResearchOncology
2018English

BRAF-mutated Metastatic Colorectal Cancer Between Past and Future

British Journal of Cancer
Cancer ResearchOncology
2015English

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy